The proposed study is a multi-center, prospective randomized controlled trial comparing current standard of care treatment to the SEXTANT treatment protocol in patients with Type III open fractures of the tibia and IIIB fractures of the ankle and hindfoot.
Specific Aim 1: To compare the surgical site infection (SSI) rates of the current severe open fracture antibiotic strategy to a revised SEXTANT treatment strategy designed to address the modern wound bioburden at the time of wound closure or coverage. Specific Aim 2: To compare the terminal bioburden of the wounds at the time of definitive closure or coverage as sampled by standard tissue microbiology. Specific Aim 3: To compare rates of antibiotic-related serious adverse events (SAEs) of the two treatment groups. Exploratory Aim 4: To pilot the use of available and emerging rapid PCR platforms for wound pathogen identification in a sub-cohort of patients.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
1,200
Participants in the control group will receive standard of care treatment for their injury, to include all institution specific standard treatment (prophylactic and otherwise) for preventing and treating infection.
The patients in the SEXTANT cohort will have 1000 mg of Vancomycin and 1200 mg of Tobramycin administered to the wound surface, fracture site and exposed hardware (if any) just prior to suture closure of the wound or flap. The SEXTANT cohort will then receive at least 72 hours of systemic antibiotic therapy targeted to the modern wound bioburden.
Deep surgical site infection
To compare the surgical site infection (SSI) rates of the current severe open fracture antibiotic strategy to a revised SEXTANT treatment strategy designed to address the modern wound bioburden at the time of wound closure or coverage.
Time frame: 182 days from injury
Deep surgical site infection
To compare the surgical site infection (SSI) rates of the current severe open fracture antibiotic strategy to a revised SEXTANT treatment strategy designed to address the modern wound bioburden at the time of wound closure or coverage.
Time frame: 365 days from injury
Fracture revision rates
Fracture revision rates for non-union, flap failure, amputation, the development of resistant bacteria discovered at revision surgery and antibiotic-related complications (C. difficile, nephrotoxicity, ototoxicity).
Time frame: 365 days from injury
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Stanford University
Redwood City, California, United States
RECRUITING_University of California, San Francisco
San Francisco, California, United States
RECRUITINGUniversity of California at San Francisco
San Francisco, California, United States
RECRUITINGUniversity of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
RECRUITINGSt Mary's University/Tenent Health
West Palm Beach, Florida, United States
RECRUITINGEmory University School of Medicine
Atlanta, Georgia, United States
RECRUITINGIndiana University School of Medicine - Methodist Hospital
Indianapolis, Indiana, United States
RECRUITINGIndiana University/Eskenazi Health
Indianapolis, Indiana, United States
RECRUITINGUniversity of Kentucky
Lexington, Kentucky, United States
RECRUITINGLSU Health Sciences
New Orleans, Louisiana, United States
RECRUITING...and 21 more locations